Pfizer Inc PFE:NYSE

Last Price$44.08NYSE Previous Close - Last Trade as of 7:00PM ET 9/23/22
NYSE 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$44.07 (1)
Ask (Size)$44.15 (20)
Day Low / HighN/A - N/A
Volume18.9 M
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 09/23/2022

 

Pfizer Inc ( NYSE )

Price: $44.08
Change: -0.49 (1.10%)
Volume: 18.9 M
7:00PM ET 9/23/2022
 
 

Abbvie Inc ( NYSE )

Price: $143.06
Change: +0.05 (0.03%)
Volume: 5.8 M
7:00PM ET 9/23/2022
 
 

Merck & Co Inc ( NYSE )

Price: $86.78
Change: -0.73 (0.83%)
Volume: 9.0 M
7:00PM ET 9/23/2022
 
 

Eli Lilly and Co ( NYSE )

Price: $311.46
Change: +0.59 (0.19%)
Volume: 4.6 M
7:00PM ET 9/23/2022
 
 

Bristol-Myers Squibb Co ( NYSE )

Price: $70.71
Change: -0.58 (0.81%)
Volume: 8.2 M
7:00PM ET 9/23/2022
 

Read more news Recent News

Market Chatter: US Reportedly Amends Pfizer's COVID-19 Vaccine Contract on Waning Demand; Shares Tick Down After Hours
5:36PM ET 9/22/2022 MT Newswires

The US government has revised its COVID-19 vaccine donations contract with Pfizer (PFE) due to waning global demand, Bloomberg reported late Thursday,...

--Pfizer Maintains Quarterly Dividend at $0.40 Per Share, Payable Dec. 5 to Holders of Record Nov. 4
9:53AM ET 9/22/2022 MT Newswires

Price: 44.10, Change: +0.18, Percent Change: +0.41 ...

Pfizer to Supply Six Million Treatment Courses of Paxlovid to Global Fund
7:09AM ET 9/22/2022 MT Newswires

Pfizer (PFE) said Thursday it agreed to supply up to six million treatment courses of its coronavirus antiviral pill Paxlovid to Global Fund as part of its...

Blackstone Joins Major Global Companies in Committing to Hire Thousands of Refugees by 2025
11:54AM ET 9/20/2022 MT Newswires

Blackstone (BX) said Tuesday it has joined several other major companies in an ongoing refugee settlement initiative with commitments to hire displaced...

View all Commentary and Analysis

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
8:10AM ET 9/23/2022 Zacks

The traditional ways to plan for your retirement may mean income can no longer cover expenses...

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
8:10AM ET 9/23/2022 Zacks

The traditional ways to plan for your retirement may mean income can no longer cover expenses...

Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2022 Update
9:11PM ET 9/22/2022 Seeking Alpha

The SEC Has Officially Cleared Cassava Sciences
8:00AM ET 9/22/2022 Seeking Alpha

Company Profile

Business DescriptionPfizer Inc. is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY. View company web site for more details
Address235 East 42nd Street
New York, New York 10017-5755
Phone+1.212.733.2323
Number of Employees92,400
Recent SEC Filing09/16/20224
Chairman, Chief Executive & Operating OfficerAlbert Bourla
Chief Financial Officer & Executive Vice PresidentDavid M. Denton
Chief Scientific Officer & Research PresidentMikael Dolsten
Chief Medical OfficerAida Habtezion

Company Highlights

Price Open$44.44
Previous Close$44.57
52 Week Range$40.94 - 61.71
Market Capitalization$247.4 B
Shares Outstanding5.6 B
SectorHealth Technology
IndustryPharmaceuticals: Major
Current Dividend / Yield$0.40 / 3.63%
Dividend Ex-Date11/03/2022
Dividend Pay-Date12/05/2022
Dividend Yield 5 Year Average3.46%
Next Earnings Announcement11/01/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings8.63
Earnings per Share$5.51
Beta vs. S&P 500N/A
Revenue$53.6 B
Net Profit Margin29.09%
Return on Equity36.56%

Analyst Ratings as of 09/16/2022

Buy
10
Overweight
0
Hold
13
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset